Vaginal progesterone for the prevention of neonatal Respiratory Distress Syndrome - a randomised controlled trial

阴道黄体酮预防新生儿呼吸窘迫综合征 - 一项随机对照试验

• 批准号: nhmrc : 399137
• 负责人: Dr Andrew Mcphee
• 金额: $ 82.89万
• 依托单位: The University of Adelaide
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2006
• 资助国家: 澳大利亚
• 起止时间: 2006-01-01 至 2008-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/vaginal-progesterone-prevention-controlled-trial/95829
• 关键词: Vaginal; progesterone; prevention; neonatal; Respiratory

Respiratory Distress Syndrome is a significant problem for babies born very preterm (at less than 34 weeks of pregnancy). For these babies, over 90% will require support for their breathing. These babies are also at increased risk of dying, and in survivors, there is a risk of long-term disability. It is uncertain if giving vaginal progesterone therapy during pregnancy to women who have had a previous preterm birth can reduce these risks. This randomised controlled trial will assess the use of vaginal progesterone therapy for women at risk of preterm birth as a means of reducing the risk of neonatal Respiratory Distress Syndrome and improving the outcomes of their babies.

呼吸窘迫综合症是早产儿（少于34周）的一个严重问题。对于这些婴儿来说，超过90%的婴儿需要呼吸支持。这些婴儿的死亡风险也在增加，而幸存者则有长期残疾的风险。对于有过早产史的妇女，在怀孕期间给予阴道孕酮治疗是否能降低这些风险尚不确定。这项随机对照试验将评估阴道孕酮治疗对有早产风险的妇女的使用，作为降低新生儿呼吸窘迫综合征风险和改善婴儿结局的一种手段。